These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 21908201)

  • 1. Strategies for maintenance therapy in advanced non-small cell lung cancer: current status, unanswered questions and future directions.
    Custodio A; de Castro J
    Crit Rev Oncol Hematol; 2012 Jun; 82(3):338-60. PubMed ID: 21908201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
    Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
    Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line treatment for non-small-cell lung cancer: one size does not fit all.
    Caponi S; Vasile E; Ginocchi L; Tibaldi C; Borghi F; D'Incecco A; Lucchesi M; Caparello C; Andreuccetti M; Falcone A
    Clin Lung Cancer; 2010 Sep; 11(5):320-7. PubMed ID: 20837457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
    Gridelli C; Brodowicz T; Langer CJ; Peterson P; Islam M; Guba SC; Moore P; Visseren-Grul CM; Scagliotti G
    Clin Lung Cancer; 2012 Sep; 13(5):340-6. PubMed ID: 22266043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy.
    Walzer S; Chouaid C; Lister J; Gultyaev D; Vergnenegre A; de Marinis F; Meng J; de Castro Carpeno J; Crott R; Kleman M; Ngoh C
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):121-8. PubMed ID: 25248391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection.
    Ramalingam S; Sandler AB
    Oncologist; 2006 Jun; 11(6):655-65. PubMed ID: 16794244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase IIIb trial evaluating the continuation of bevacizumab beyond disease progression in patients with advanced non-squamous non-small-cell lung cancer after first-line treatment with bevacizumab plus platinum-based chemotherapy: treatment rationale and protocol dynamics of the AvaALL (MO22097) trial.
    Gridelli C; Bennouna J; de Castro J; Dingemans AM; Griesinger F; Grossi F; Rossi A; Thatcher N; Wong EK; Langer C
    Clin Lung Cancer; 2011 Nov; 12(6):407-11. PubMed ID: 21705281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PARAMOUNT trial: a phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Rev Recent Clin Trials; 2013 Mar; 8(1):23-8. PubMed ID: 23259416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maintenance or non-maintenance therapy in the treatment of advanced non-small cell lung cancer: that is the question.
    Galetta D; Rossi A; Pisconti S; Millaku A; Colucci G
    Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S30-3. PubMed ID: 21129607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH; Hirabayashi M; Togashi Y; Hirano K; Tomii K; Masago K; Kaneda T; Yoshimatsu H; Otsuka K; Mio T; Tomioka H; Suzuki Y; Mishima M
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):271-6. PubMed ID: 22752216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for second-line therapy of non-small cell lung cancer.
    Stinchcombe TE; Socinski MA
    Oncologist; 2008; 13 Suppl 1():28-36. PubMed ID: 18263772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemetrexed in advanced non-small-cell lung cancer.
    Fuld AD; Dragnev KH; Rigas JR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1387-402. PubMed ID: 20446853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamous non-small-cell lung cancer (ERACLE).
    Galetta D; Pisconti S; Cinieri S; Pappagallo GL; Gebbia V; Borsellino N; Maiello E; Rinaldi A; Montrone M; Rizzo P; Marzano N; Sasso N; Febbraro A; Colucci G
    Clin Lung Cancer; 2011 Nov; 12(6):402-6. PubMed ID: 21831718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
    Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: current status and future challenges.
    Pallis AG; Syrigos K
    Cancer Treat Rev; 2012 Nov; 38(7):861-7. PubMed ID: 22217701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.